This is because a number of anti-TNF agents, including infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab, are widely used to treat inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis (64). This evidence concerns the gene TNF and inflammatory bowel disease.